Evidence map›Paper›PMID 39760831›Full record

ReviewNeurology and therapy2025

Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel.

Miquel Bernardo, Marina Díaz Marsá, Ana González-Pinto, Manuel Martín Carrasco, Víctor Pérez Sola, Pilar Alejandra Sáiz, Eduard Vieta, Marta Torrens, Celso Arango, Benedicto Crespo-Facorro

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Miquel BernardoDepartment of Psychiatry and Psychology, Clínic Barcelona, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain. BERNARDO@clinic.cat.ORCID http://orcid.org/0000-0001-8748-6717
Marina Díaz MarsáHospital Clínico San Carlos, Universidad Complutense, CIBERSAM, Madrid, Spain.ORCID http://orcid.org/0000-0003-1364-3163
Ana González-PintoHospital Universitario de Álava, BIOARABA. UPV/EHU, CIBERSAM, Vitoria, Spain.ORCID http://orcid.org/0000-0002-2568-5179
Manuel Martín CarrascoClínica Psiquiátrica Padre Menni, Pamplona, FIDMAG Research Foundation, Barcelona, Spain.ORCID http://orcid.org/0009-0005-8718-9356
Víctor Pérez SolaMental Health Institute Hospital del Mar, Barcelona, Hospital del Mar Research Institute, University Pompeu Fabra, University of Vic-Central Catalunya, RIAPAD, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5825-2337
Pilar Alejandra SáizDepartment of Psychiatry, Universidad de Oviedo, CIBERSAM, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Neurociencias del Principado de Asturias (INEUROPA), Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain.ORCID http://orcid.org/0000-0002-5705-4523
Eduard VietaDepartment of Psychiatry and Psychology, Clínic Barcelona, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.ORCID http://orcid.org/0000-0002-0548-0053
Marta TorrensMental Health Institute Hospital del Mar, Barcelona, Hospital del Mar Research Institute, University Pompeu Fabra, University of Vic-Central Catalunya, RIAPAD, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6222-4761
Celso ArangoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.ORCID http://orcid.org/0000-0003-3382-4754
Benedicto Crespo-FacorroDepartment of Psychiatry, Faculty of Medicine, Mental Health Unit, Virgen del Rocio University Hospital, Translational Psychiatry Group, IBiS-CSIC, CIBERSAM, University of Seville, Seville, Spain.ORCID http://orcid.org/0000-0003-0033-7132

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFor patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13-17 years). The efficacy and tolerability of lurasidone have been demonstrated in both antipsychotic-naïve and previously treated patients. AREAS COVERED: This paper provides a review and commentary regarding the use of lurasidone in patients with FEP. Case studies based on the authors' clinical experiences with lurasidone in real-world practice are provided. EXPERT OPINION: In our experience, lurasidone has shown efficacy in FEP in different patient profiles, including those with psychoses associated with substance use disorders. Lurasidone provides clinically relevant benefits, especially in patients with affective symptomatology, and has a good tolerability profile.

Indexed as

AntipsychoticFirst-episode psychosisLurasidoneSchizophreniaTolerabilityTreatment

Identifiers

PMID39760831
PMCPMC11762036

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.